|
|
Pipeline Overview
| |
Product |
Basic
Research |
Animal
Studies |
Phase
I / II |
Phase
III |
Key 2012
Milestones |
Market Size
(US$m) |
TEPA
Copper Chelator
Technology |
StemEx® |
Hematological Malignancies |
Phase III data |
>1,000 |
Nicotinamide
NAM Technology |
NiCord® |
Hematological Malignancies |
Phase III data |
>1,000 |
| NiCord® |
Hemoglobinopathies * |
Phase I/II
preliminary data |
>3,000 |
| CordBridge™ |
Neutropenia & ARS |
Begin Phase I/II |
>50,000 |
Natural Killer
Cells |
Solid & Hematological Malignancies |
Begin Phase I/II
in collaboration
with the NIH |
>30,000 |
Mesenchymal
Stem Cells |
Regenerative Medicine |
Preclinical |
>50,000 |
* Includes Sickle Cell Disease and Thalassemia
|
